SHOW DIRECTORY
Gradient Dissent
Lukas Biewald speaks with AI leaders about cutting-edge machine learning and the practical intricacies of bringing models into production.
SOURCE DESCRIPTION · RSS
From pharma to AGI hype, and developing AI in finance: Martin Shkreli’s journey
AI’s largest biopharma opportunity may be target selection rather than molecule generation, with an LLM reading roughly 36-38 million PubMed papers to identify overlooked clinical opportunities.BTK illustrates the mechanism: valuable research sat published for 15-20 years, while clinical trials still consume 50-70% of total cost and development cycles approach ten years.Shkreli’s finance suite found millions of dollars in revenue after abandoning forced AI positioning, but breaking-news advantages may diffuse across Wall Street within six months to a year.